Accenture Solutions Private
Accenture Solutions Private is recorded as a service provider in 89 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 89 trials · Latest update first
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
Sponsor Mirati Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-2)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression ≥1%
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents from 5 to less than 18 Years of Age with Active Juvenile Psoriatic Arthritis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CheckMate 9DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9DX)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants with Sickle Cell Disease to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability, pH and Food Effect, and Preliminary Efficacy of BMS-986470
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Enrollment to the nivolumab plus relatlimab 960 mg group was stopped on 19 July 2021 after two participants in that group died, to protect participant safety.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or had Previously Received TNFα Inhibitor Treatment
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder (BALSAM-3)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Accenture Solutions Private?
The 2026-10-09 snapshot links Accenture Solutions Private to 89 distinct CTIS trials. Recorded services include Data management, Embarc operations, Safety reporting & pharmacovigilance, submission administrative support, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Accenture Solutions Private?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Haematological Malignancies, Dermatology, Psychiatry. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Accenture Solutions Private conducted?
The linked trials record locations in 21 countries, including Spain, Italy, France, Germany, Poland. These are trial locations, not confirmed office locations or countries where Accenture Solutions Private delivered services.
What can this page tell me about Accenture Solutions Private's trial experience?
Browse 89 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 4 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Accenture Solutions Private. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Accenture Solutions Private Limited